“These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?”
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices.
(New York Times article, October 2, 2018)
READ MORE